Abstract
Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.
Original language | English |
---|---|
Number of pages | 5 |
Journal | British Journal of Cancer |
Publication status | Published - 2008 |
Keywords
- LMO4
- cancer
- pancreas
- prognosis
- surgical resection
- therapeutic response